74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Sana Biotechnology Inc
Closed
SectorHealthcare
4.19 -2.1
Overview
Share price change
24h
Min
4.16
Max
4.22
Income | 52M -42M |
|---|---|
Employees | 194 |
EBITDA | 56M -39M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +63.93% upside |
Next Earnings | 13 Mar 2026 |
|---|
Market Cap | -92M 1.1B |
|---|---|
Previous open | 6.29 |
Previous close | 4.19 |
News Sentiment
By Acuity
50%
50%
149 / 352 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Sana Biotechnology Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sana Biotechnology Inc Forecast
Price Target
By TipRanks
63.93% upside
12 Months Forecast
Average 7 USD 63.93%
High 7 USD
Low 7 USD
Based on 1 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.
Sentiment
By Acuity
149 / 352 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Live chat